CARLSBAD, Calif.--(BUSINESS WIRE)--Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, today announced the introduction of its Invivofectamine™ delivery reagent which enables short interference ribonucleic acid (siRNA) experiments in vivo.
